Acute lymphoblastic leukemia (ALL) is the most common malignancy affecting children and a major cause of mortality from hematopoietic malignancies in adults. A substantial number of patients become drug resistant during chemotherapy, necessitating the development of alternative modes of treatment. rGel (recombinant Gelonin)/BlyS (B-lymphocyte stimulator) is a toxin-cytokine fusion protein used for selective killing of malignant B-cells expressing receptors for B-cell-activating factor (BAFF/BLyS) by receptor-targeted delivery of the toxin, Gelonin. Here, we demonstrate that rGel/BLyS binds to ALL cells expressing BAFF receptor (BAFF-R) and upon internalization, it induces apoptosis of these cells and causes downregulation of survival genes even in the presence of stromal protection. Using an immunodeficient transplant model for human ALL, we show that rGel/BLyS prolongs survival of both Philadelphia chromosome-positive and negative ALL-bearing mice. Furthermore, we used AMD3100, a CXCR4 antagonist, to mobilize the leukemic cells protected in the bone marrow (BM) microenvironment and the combination with rGel/BLyS resulted in a significant reduction of the tumor load in the BM and complete eradication of ALL cells from the circulation. Thus, a combination treatment with the B-cell-specific fusion toxin rGel/BLyS and the mobilizing agent AMD3100 could be an effective alternative approach to chemotherapy for the treatment of primary and relapsed ALL.
INTRODUCTION
Precursor B-lineage acute lymphoblastic leukemia (ALL) is the most common type of leukemia in children up to 9 years of age. In the USA, ALL additionally represents around 1/3 of all cases of adult leukemias. 1, 2 In such patients, accumulation of blasts at the pre-B stage of differentiation, initially in the bone marrow (BM), is followed by subsequent infiltration at various other peripheral sites. 3, 4 Treatment usually consists of vincristine, prednisone and anthracycline with or without asparaginase. Those patients that are cured may experience long-term side effects due to the treatment with nonselective cytotoxic drugs. However, relapse during or after treatment remains the most urgent short-term challenge facing patients with ALL. 5 --7 Unfortunately, there is a limit to what can be accomplished with the addition of nonselective cytotoxic agents owing to systemic toxicity.
A frequent site of relapse is the BM, 8, 9 which may be a particularly natural protective site for such cells. Therefore, we and others are focusing on the BM microenvironment as a possible target for treatment by investigating the interactions between cell surface receptors on the ALL cells that are engaged by factors produced in the BM. Recently, we were the first to report that pre-B ALL cells express the B-cell-activating factor receptor (BAFF-R). 10 Although this receptor was originally identified only on more mature B-lineage cells, we and others found that many pre-B ALLs, including both cell lines and patient samples, express cell surface BAFF-R, 10 --13 but we were unable to detect it on normal BM pre-B cells.
The BAFF-R has a single ligand called BAFF, known also as BLyS, (B-lymphocyte stimulator), which is produced by dendritic cells, monocytes, BM stromal cells and macrophages. In macrophages, expression is induced not only by pro-inflammatory stimuli, such as interferon-g, but also by interleukin-10 (IL-10). Besides the BAFF-R, there are two other receptors that bind BAFF: BCMA (B-cell maturation antigen), and TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor). 14 --19 Expression of all three is mainly found on B-lineage hematopoietic cells, and the best characterized functions are in plasma cells and naïve and memory B cells, 20 --22 where they co-stimulate proliferation and promote survival of these mature B cells in vitro and in vivo. 14, 15 The BAFF-R expression on normal mature B cells is maintained in B-lineage malignancies, such as mantle cell lymphoma, chronic lymphocytic leukemia and diffuse large-B-cell lymphoma. 23 --25 Lyu et al. 25 recently generated a recombinant fusion protein between Gelonin and BAFF (BLyS) for the specific delivery of Gelonin to malignant mature B cells expressing BAFF receptors. Gelonin is a plant toxin, which inhibits protein synthesis by inactivating ribosomes. It cannot enter the cells by itself as it lacks the ability to bind to the cell surface. 26 Thus, although recombinant Gelonin (rGel) alone is ineffective in killing cells, fusion constructs and immunotoxins made with rGel were reported to successfully kill malignant cells. 27 --33 Interestingly, rGel/BLyS inhibited the growth of diffuse large-B cell lymphoma in vitro and in vivo and induced apoptosis in chronic lymphocytic leukemia cells. 31, 33 The expression of the BAFF-R on pre-B ALL (80 --99%, as detected by FACS analysis) 10 prompted us to investigate if this targeted construct could be utilized as a basis to eradicate them. We here report that rGel/BLyS is a very promising therapeutic agent with selective cytotoxicity mediated by its fusion to the ligand for the BAFF-R. Moreover, by combining this selective but toxic fusion protein with a nontoxic ALL-mobilizing agent, we were able to significantly deplete the pool of malignant lymphoblasts in vivo that could form the basis for relapse in the BM.
MATERIALS AND METHODS
Reagents and antibodies AMD3100 octahydrochloridehydrate (1, 1 0 -(1, 4-phenylene bis(methylene) bis-1, 4, 8, 11 tetra azacyclotetradecane octahydrochloride) was purchased from Sigma-Aldrich (St Louis, MO, USA). The rGel/BLyS protein, consisting of Gelonin fused to the N-terminus of human BLyS, was expressed in E.coli as previously described. 25 Antibodies used are described in Supplementary Methods.
Evaluation of binding of rGel/BLyS to ALL cells ALL cells used here originate from primary human isolates that have been passaged in NOD/SCID/IL2rgÀ/À (NSG) mice and were described previously. 10, 34 In brief, US.7 and US.7R were from one patient before and after the development of resistance against treatment; BLQ-1, P-2 and TXL2 are Ph-positive ALLs with and without the T315I mutation in Bcr/Abl. All ALLs were grown on irradiated OP9 feeder layers as previously described. 10 For evaluation of their ability to bind to rGel/BLyS, they were incubated with 400 nM rGel/BLyS (recombinant Gelonin --BLyS fusion protein) or rGel (recombinant Gelonin) for 2 h at 37 1C, washed with PBS, fixed, permeabilized and incubated with a polyclonal rabbit anti-Gelonin antibody followed by a FITC conjugated secondary antibody and analyzed by FACS (Accuri flow cytometers Inc., Ann Arbor, MI, USA). Immunohistochemistry using an anti-Gelonin antibody was performed on permeabilized US.7 cells. For competition assays, US.7 ALL cells were pre-incubated with recombinant human BAFF or anti BAFF-R antibody for 2 h, followed by incubation for 2 h with 100 nM rGel/BLyS. BAFF-R Fc and rGel/BLyS were added together for the 2 h incubation. Cells were next washed with PBS and detection of binding of the rGel/BLyS fusion protein was done as described above. To detect intracellular survival proteins by FACS, cells were fixed, permeabilized using fixation and permeabilization buffers according to the manufacturer's instructions (eBioscience, San Diego, CA, USA), incubated with specific antibodies (45 min, room temperature) and washed with PBS before analysis.
In vitro treatment
For CXCR4 detection, ALL cells were incubated with 1 mM AMD3100 for 24 h. Cells were collected, washed with PBS, incubated with anti-human CXCR4 antibody for 30 min, washed with PBS and analyzed by flow cytometry. Appropriate isotype antibodies and cells without AMD3100 treatment served as controls. For migration assays, SDF-1a (200 ng/ml) or OP9 stromal cells were added to the lower wells of a 5-mm pore transwell. After 24 h, ALL cells were treated with AMD3100 (10 mM) for 30 min at 4 1C, seeded at 5 Â 10 4 cells in the upper wells and incubated for 90 min. Nonadherent cells were collected from the lower wells and counted using an automated cell counter. Wells without SDF-1a or OP-9 cells served as controls. For adhesion assays, US.7 cells and OP-9 cells were co-cultured for 2 weeks. Floating US.7 cells were removed by gentle washing using medium. At this time, almost all the US.7 cells present were under the stromal layer. AMD3100 (10 mM) together with fresh medium was added to the co-culture plates. Non-adherent cells were counted after 2, 6, 10 and 24 h of incubation. US.7 cells treated the same way without AMD3100 served as controls. For in vitro combination treatment using rGel/BLyS and AMD3100, drugs were added in different combinations as described in the Figure 5 legend. Annexin V staining was done according to the manufacturer's (BD Pharmingen, San Jose, CA, USA) instructions. For detection of NF-kB (p65), a nuclear extraction kit (Imgenex, San Diego, CA, USA) was used to separate nuclear and cytoplasmic fractions. In all, 30 mg of nuclear protein was loaded in each well. Western blots were incubated overnight with primary antibody. Cell viability in all experiments was determined by Trypan blue exclusion.
Human ALL transplant model
All animal experiments were carried out in concordance with Institutional IACUC and NIH guidelines. Human ALL cells were injected at 1.5 Â 10 6 cells/animal (US.7) or 3 Â 10 6 cells/animal (TXL-2) into NSG mice. Cells were allowed to proliferate in vivo for 6 days before start of treatment, at which point all mice had a similar amount of CD10 þ , CD19 þ cells in their peripheral blood (PB) ( Supplementary Figure 2A) . US.7 transplanted mice (n ¼ 6/group) were injected i.p. during days 6 --25 for a total of 6 Â with PBS or 6 Â with rGel/BLyS (3.75 mg/kg). TXL-2-transplanted mice (n ¼ 5/ group; n ¼ 6/group for body weight measurements of groups (c) and (d) below) were treated from days 6 --33 with (a) 8 Â PBS (b) 3 Â PBS followed by 5 Â AMD3100 (10 mg/kg) (c) 8 Â with rGel/BLyS (2.75 mg/kg) or (d) 8 Â with rGel/BLyS plus 5 Â with AMD3100. Supplementary methods provide additional experimental details.
Statistical analysis
All in vitro experiments were done in triplicate and on triplicate samples. Student's t-test was performed to assess statistical significance of the results. The significance of survival was analyzed using the log rank test.
RESULTS

rGel/BLyS binds to human pre-B ALL cells
We used both Ph-negative (US.7, US.7R) and Ph-positive (TXL-2, BLQ-1) ALL cells to examine if the rGel/BLyS fusion protein is able to bind to the BAFF-R expressed by pre-B ALL cells. After a 2-h incubation of ALL cells with rGel/BLyS fusion protein or with control rGel, we examined the presence of these proteins in and on the ALL cells using a Gelonin-specific antibody. As shown in Figure 1a , rGel-treated cells showed no staining with anti-Gelonin antibodies (black line) and little rGel/BLyS (blue line) was detected on the surface of the cells. However, a clear positive signal in permeabilized cells indicates that rGel/BLyS had been internalized (Figure 1a , red line). This confirmed that Gelonin is unable to cross the plasma membrane without conjugation to BLyS. We also demonstrated the intracellular presence of rGel/BLyS by fluorescent microscopy (Figure 1b ). To investigate the specificity of rGel/BLyS binding to the BAFF-R on the pre-B ALL cells, US.7 cells were either pre-treated with recombinant BAFF, with antibodies to BAFF-R (2 h before addition of rGel/BLyS) or with recombinant BAFF-R Fc (added together with rGel/BLyS). As evidenced by FACS analysis on permeabilized cells (Figure 1c ), BAFF, BAFF-R antibody and BAFF-R Fc inhibited rGel/BLyS detection in US.7 cells in a dose-dependent manner. Thus, rGel/BLyS failed to bind to the BAFF-R when these receptors were pre-occupied with recombinant BAFF or BAFF-R antibody.
rGel/BLyS induces apoptosis of human ALL cells
We next examined the effect of rGel/BLyS on the growth of ALL cells. As shown in Figure 2a , rGel/BLyS induced apoptosis in a dose-dependent manner in US.7 cells after 3 days of treatment. Although higher concentrations of rGel/BLyS augmented the killing of US.7 cells, we chose the lowest dose of 100 nM for further studies because it has been shown that Gelonin causes toxicity to mammalian cells over an extended period, killing cells within 3 --4 days by inhibiting protein synthesis. 33 We also compared the sensitivity of different ALL cells to this toxin-BLyS conjugate. As shown in Figure 2b , 100 nM rGel/BLyS treatment decreased cell viability significantly in all treated cells as measured after 7 days of treatment. Extension of the US.7 culture and treatment with rGel/BLyS treatment downregulates survival genes and inhibits NF-kB activation in ALL cells Vincristine is a commonly used toxic chemotherapeutic agent for the treatment of ALL. We therefore further compared the cytotoxic effect of rGel/BLyS to that of vincristine as monotreatment using US.7 cells. As shown in Figure 3a ALL cells express high levels of survival proteins such as Bcl-x L , Bcl-2, Survivin and Mcl-1. 35 --37 To investigate if the expression of these genes is affected by uptake of rGel/BLyS, we examined their baseline expression by FACS and after rGel/BLyS or rGel treatment. Interestingly, as shown in Figure 3b , Bcl-x L and Mcl-1 levels were very obviously reduced in rGel/BLyS-treated cells, whereas inhibition of Bcl-2 and Survivin expression was much less pronounced. As these pro-survival genes are under NF-kB transcriptional regulation, 38, 39 we also compared NF-kB activation in the rGel/BlyS-and rGel-treated cells. Figure 3c shows constitutive NF-kB activation in untreated ALL cells as measured by the presence of nuclear p65 and, unlike rGel treatment, rGel/ BLyS treatment inhibited the nuclear translocation of NF-kB-p65 in a dose-dependent manner.
rGel/BLyS prolongs the survival of NSG leukemic mice
To investigate to what extent rGel/BLyS binds to nonleukemic B cells, we incubated it with mouse B220 þ cells from BM and spleen as well as with human CD19 þ cells from PB and BM. B cells from human or murine BM, or mouse spleen showed no binding to rGel/BLyS, whereas B cells from human PB showed appreciable binding (Supplementary Figure 1A) . We also assessed toxicity of rGel/BLyS on normal mouse B cells in vivo. rGel/BLyS (3.75 mg/kg) was administered biweekly for 3 weeks to C57BL/6 mice, after which B cells from BM and spleen were examined. To confirm the presence of Gelonin in BM of rGel/BlyS-injected mice, BM lysates were prepared 5 h after rGel/BLyS injection. Western blots with anti-Gelonin antibodies confirmed the presence of rGel/BLyS in BM of mice injected with rGel/BLyS but not of controls ( Supplementary Figure 1B) . B-cell populations in both BM and spleen (Supplementary Figures 1C, D) were comparable in treated and control mice based on FACS, indicating that no specific B-lineage populations were ablated. Analysis of serum for LDH activity and histological examination of liver did not provide evidence of tissue damage or liver toxicity in the rGel/BLyS-injected mice compared with controls ( Supplementary  Figures 1E, F) .
We next examined the ability of rGel/BLyS to suppress pre-B ALL growth in an in vivo NSG mouse model of human ALL. We transplanted US.7 cells into NSG mice and allowed the cells to proliferate for 6 days to form an appreciable tumor burden, as detected by FACS analysis of PB ( Supplementary Figure 2A) . Then 3.75 mg/kg rGel/BLyS was administered bi-weekly for 3 weeks (Figure 4a ). Mice not receiving treatment had to be killed at around day 34, whereas mice treated with rGel/BLyS survived significantly (P ¼ 0.002) longer (Figure 4b ). Remarkably, FACS analysis of PB from mice treated with rGel/BLyS, using human CD19 and CD10 antibodies, showed that the treatment had eliminated virtually all circulating leukemia cells (Figure 4c ). However, the BM of these mice clearly contained leukemic cells (Figure 4d ). We considered the possibility that the relapsed ALL cells in the BM were selected for loss of BAFF-R expression and thus escaped from rGel/BLyS-induced apoptosis. However, FACS analysis of the ALL cells in the BM of rGel/BlyS-treated mice demonstrated that these cells uniformly expressed high levels of the BAFF-R (Figure 4e ). AMD3100 mobilizes and sensitizes ALL cells to rGel/BLyS treatment It is thought that leukemic cells are protected by the BM microenvironment against the cytotoxic effects of drugs and we interpreted the BM relapse of BAFF-R-positive ALL cells in rGel/BLyS-treated mice as a typical outcome of chemotherapy. As the interaction of the chemokine receptor CXCR4 on pre-B ALL cells with SDF-1a produced by BM stroma has been identified as a key factor in retention of ALL cells in the BM, 40, 41 we tested the efficacy of AMD3100, a CXCR4 antagonist, in mobilizing ALL cells in vitro. The interaction of AMD3100 with CXCR4 blocks the binding of anti-CXCR4 monoclonal antibodies to the receptor and this correlates directly with SDF-1 inhibition. 42, 43 Therefore, to assess the binding of AMD3100 with human ALL cells, CXCR4 expression was analyzed by FACS with or without incubation with AMD3100. As shown in Figure 5a , AMD3100 treatment reduced cell surface CXCR4 detection up to 40% compared with the respective control cells without AMD3100 treatment. To investigate whether AMD3100 is able to disrupt an adhesion that was already established, we co-cultured ALL cells with OP9 feeder layers. Under these conditions, most of the leukemia cells associate with the feeder layer. After 2 weeks of culture, the culture supernatant was removed and replaced with medium containing AMD3100. As shown in Figure 5b , AMD3100 had a marked mobilizing activity in vitro. SDF-1a is a strong chemotactic agent for lymphoblasts and BM stromal cells are good producers of this chemokine. 41, 44 We next tested whether AMD3100 could block the migration of leukemic cells towards SDF-1a as well as stroma. As shown in Figures 5c and d , pre-incubation of the ALL cells with AMD3100 significantly blocked the SDF-1a-directed (c) as well as stroma-directed (d) chemotaxis.
G-CSF is clinically used to mobilize stem cells from the BM and is known to induce the disruption of the CXCR4/SDF-1a chemotactic interaction during hematopoietic stem cell mobilization. 45 However, G-CSF alone did not show an improved mobilizing effect in US.7 cells compared with AMD3100. We therefore also tested the combined effect of G-CSF with AMD3100 to further increase mobilization of these cells, but found no added benefit of the combination beyond AMD3100 alone ( Supplementary Figure 3) .
We next performed a long-term treatment of TXL-2 and US.7 cells in vitro with rGel/BLyS in combination with AMD3100 in the presence of stroma (Figures 5e and f) . Viability of cells treated with AMD3100 alone did not change significantly. Cultures treated only with rGel/BLyS decreased in viability over a period of 17 days (TXL-2) or 14 days (US.7) but, similar to the results shown in Figure 3 , even after extended treatment with rGel/BLyS as a single agent, resistance to treatment was evident ( Supplementary Figure 4) . When we added AMD3100 and rGel/BLyS together at day t ¼ 1, viability was very similar to rGel/BLyS alone cultures. (Figures 5e  and f, compare black triangles and squares) . The best outcome was achieved when rGel/BLyS was added as monotherapy for the first 5 days and then AMD3100 was combined with it (Figures 5e and f and Supplementary Figures 4A and B) .
Combination therapy using rGel/BLyS and AMD3100 results in significantly reduced leukemia burden in BM We translated our in vitro observations to an in vivo experiment. For in vivo combination treatments, we used NSG mice transplanted with Ph-positive TXL-2 ALL cells to study the effect of AMD3100 in combination with rGel/BLyS in killing ALL cells. Mice were treated with PBS, AMD3100 alone, rGel/BLyS alone or rGel/BLyS þ AMD3100. In the combination group, mice were first treated with rGel/BLyS alone to reduce the overall leukemia burden. When AMD3100 was added on to this treatment, we injected the AMD3100 5 --6 h before the rGel/BLyS was administered. This strategy was used to ensure the presence of circulating ALL cells at the time when the toxin would also be in the circulation. When the mice in the control and AMD3100 alone treated group lost more than 20% of their initial body weight on day 32 after transplant, they were killed. Leukemic mice treated with the combination of rGel/BLyS þ AMD3100 and rGel/BLyS alone did not show any weight loss or other symptoms of the disease at day 32. They were killed on day 46 (Figures 6a and b) , when the rGel/BLyS alone treated group had exhibited significant loss of body weight (Supplementary Figures 5A, B ). FACS analysis was performed for the presence of human ALL cells in spleen, PB, BM, lungs, liver and kidney. As expected and consistent with the in vivo experiment with US.7 cells, there was a complete eradication of ALL cells from the circulation. However, in contrast to the results with US.7-transplanted mice, in which we found high amounts of ALL cells in the BM, mice transplanted with TXL-2 cells and treated with additional applications of rGel/BLyS had a reduction of the leukemia burden in the BM (Figure 6c ). Moreover, this was reduced even further in the mice treated with both rGel/ BLyS and AMD3100. Human ALL cell numbers in the spleen were also significantly lower in the rGel/BLyS þ AMD3100-treated group (Figure 6c ). To examine ALL metastasis in other organs, we performed FACS analysis on lungs and liver cells (Figure 6c , bottom row). There was little infiltration of leukemic cells in these peripheral organs. Also, splenomegaly was not present (Supplementary Figure 5C ). rGel/BLyS in combination with AMD3100 appeared to be well tolerated as there was no weight loss in the dual treatment group (Supplementary Figure 5B) or changes in physical appearance.
To confirm the combinatorial effect of rGel/BLyS with AMD3100 in killing ALL cells, we treated mice transplanted with US.7 cells with rGel/BLyS alone or together with AMD3100 as described above. Figure 6d shows that the leukemia burden was reduced significantly in spleen, PB, BM, lungs, liver and kidney of rGel/ BLyS þ AMD3100-treated mice, compared with rGel/BLyS-alone treated mice.
DISCUSSION
As the BAFF-R was only reported on mature B-cell malignancies, the use of rGel/BLyS as an anti-leukemic agent has to date only been evaluated in this type of leukemia. Nimmanapalli et al. 33 reported that rGel/BLyS inhibits the production of fast-turnover proteins and that Bcl-2, being a long-lived protein with a half life up to 24 h, is not affected by rGel/BLyS exposure. Our data are in agreement with this, as we found that Bcl-2 expression was not significantly altered in ALL cells after rGel/BLyS treatment. However, levels of other pro-survival proteins including Bcl-x L and Mcl-1 were reduced by this treatment and we found that exposure to rGel/BLyS also inhibited the nuclear translocation of p65-NF-kB, suggesting a correlation with the expression of these pro-survival genes.
To be able to provide a superior activity in comparison with standard cytotoxic drugs, new compounds should exhibit specificity and potency. Our data showing that Gelonin alone does not bind to ALL cells or is internalized in consistent with its lack of effect on the proliferation or viability of ALL cells. The conjugation of BAFF (BLyS) to Gelonin imparts a remarkable specificity to target this toxin to cells that express receptors for BAFF (BLyS). Although BAFF (BLyS) can bind to three distinct receptors, BAFF-R, TACI and BCMA, 46, 47 there is very little if any expression of BCMA or TACI on these pre-B ALL cells 10 and thus the entry and cytotoxic effect of rGel/BLyS on pre-B ALL cells is BAFF-R receptor-mediated. Experiments to assess the toxicity of rGel/BLyS in nonleukemic mice did not yield evidence that the toxin had an effect on normal mouse B-lineage cells and is in agreement with earlier data. 26 --33 However, B cells isolated from human PB clearly showed binding to rGel/BLyS and the toxin would be expected to kill mature normal human B cells.
The potency of this fusion toxin is likely to be determined by the cytotoxicity of Gelonin once it is internalized, as well as the numbers of BAFF receptors present on the surface of the target cell. Lyu et al. 25 reported that the ability of the BLyS component of rGel/BLyS to mediate the delivery of the toxin to the target cell cytoplasm (targeting index) varied from 1 to 187 500 among 17 malignant B cells tested and this was generally correlated with the total number of BAFF receptors expressed by the cell. Of the cells tested, MCL cell lines showing the maximum sensitivity to rGel/ BLyS expressed the highest level of BAFF-R, while the HL-60 cell line, being the least sensitive to rGel/BLyS, did not express BAFF-R protein. We have previously determined that the pre-B ALL cells express high levels of BAFF-R 10 and we indeed found a profound cytotoxic effect of rGel/BLyS on these cells, which compared very favorably with the standard vincristine. In a recent publication, Maia et al. 13 showed that all of the 23 primary B-cell precursor ALL samples tested had cell surface expression of the BAFF-R, which supports the potential therapeutic application of rGel/BLyS for ALL.
The cytotoxicity of rGel/BLyS in vitro was further substantiated by its activity in an NSG ALL transplant model of established leukemia, in which six treatments were sufficient to generate a hematological remission. However, analysis of the BM showed that, although ALL cell numbers were reduced, the treatment had not eradicated the ALL cells. This could be caused by reduced or absent expression of the BAFF-R on ALL cells in that location but we found that ALL cells in the BMs of the relapsing rGel/BLyS-treated mice all had full expression of the BAFF-R. As expression of the BAFF-R will result in the specific eradication of those cells through internalization of the rGel/BLyS fusion toxin, it appears that there is strong selective pressure for the maintenance of its expression. Our previous studies, using ALL cells in co-culture with stroma, suggested that the expression of the BAFF-R provides a survival advantage to the cells 10 and provide support for this idea.
We therefore considered an alternative explanation for the presence of the ALL cells, namely that the BM presents an unusually challenging environment from the perspective of treatment with a BAFF (BLyS)-conjugate because of the high levels of competing BAFF (BLyS) that is endogenously produced by the BM microenvironment. In support of this, we had noted in our co-culture system that exogenously added recombinant human BAFF (BLyS) is able to inhibit the binding of rGel/BLyS to ALL cells in a dose-dependent manner. In addition, the presence of BAFF-R-expressing ALL cells in the BM could also be explained if the fusion toxin had limited access to the cells at that location.
To circumvent problems associated with localization of leukemic cells in the BM, we applied a strategy we have previously started to explore for ALL, and by others for AML and CML, making use of agents that are able to mobilize leukemic cells out of that location into the circulation. 48 --51 We used AMD3100, a CXCR4 antagonist, for this purpose. All parameters tested, including CXCR4 cell surface expression, adhesion to stroma, and SDF-1a or stroma-directed chemotaxis, could be inhibited by AMD3100 in ALL cells. This observation is in contradiction with a number of earlier publications suggesting that there is a weak adhesion of Bcr/Abl-positive leukemic cells to BM cells, which would make Bcr/Abl-positive ALL cells insensitive to CXCR4-mediated signals and chemotaxis towards SDF-1a. 52, 53 Moreover, we showed that in an in vitro co-culture system, treatment of Ph-positive ALL cells (TXL-2) with rGel/BLyS and AMD3100 significantly reduced viability compared with monotreatment with rGel/BLyS. These results were replicated in an in vivo transplant model. Although rGel/BLyS monotreatment eliminated circulating ALL cells, the addition of AMD3100 to the treatment significantly further reduced the amount of ALL cells present in the spleen and, importantly, in the BM. As rGel/BLyS targets only cells expressing the BAFF-R, TACI or BCMA, and because AMD3100 appears to have no cytotoxic effect at all, this treatment could potentially be expanded, if needed, to include a third drug. Moreover, as neither rGel/BLyS nor AMD3100 is currently used to treat patients with ALL, it is unlikely that relapsed patients would have ALL cells that are resistant to these drugs. We conclude that our novel treatment strategy has a very promising clinical application for both Phpositive and Ph-negative ALLs.
